- How Many US Consumers Will Shop this Weekend?
- Tuesday's Heavy Dose of Data to Dictate 'Risk' Behavior
- World's Largest Share Issue Priced at Deep Discount
- Obama says Boosting US Jobs is Top Priority
- Why the Dollar Will Likely Stay Weak for Some Time
- Playboy to Outsource Most Magazine Operations: Report
- General Motors to Cut up to 9,500 Jobs in Europe
- EU Drops Proceedings Against Qualcomm
- Appeals Court Denies Microsoft's Alcatel Petition
- Can Murdoch Help Bing Challenge Google and Shift the Content Equation?
- HP's Mark Hurd
- HP Comes in As Expected; Is It Time to Buy?
- 9 Stocks That Play Rising Water Costs: Strategists
- Weis' Deal Likely Won't Change Big Money Contracts
- Gold Prices Can Double in 3 Years: Portfolio Manager
- Nov. 23: Unusual Volume Leaders
- Help Wanted—Please Run $4 Billion University
- Apple Comes to AT&T's Rescue
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Why Amazon Rules Retail
- Wave of Debt Payments Facing US Government
- China Eastern to Complete Shanghai Air Buy by End '09
- Paul: Audit the Fed
- The Social Media Gaming Threat
- Gold Will Collapse Like Oil Did in 2008: Charts
- Prepare For Large Decline In Stocks, Next Year?
- JAL Slides to Record Low on Bankruptcy Jitters
- Lyondell Urged to Consider Reliance Takeover Offer
Text Size 
Dendreon has completed its U.S. regulatory submission for its closely watched experimental prostate cancer vaccine, the company said Monday, sending its shares up 5 percent.
 |
CNBC.com |
Dendreon previously said it expected to seek U.S. approval for Provenge in November, and expected regulators to respond by mid-2010.
"The submission came a little earlier than had been expected, which was in mid-November, so that is a positive," said Canaccord Adams analyst George Farmer, who estimated the product's sales potential at greater than $4 billion annually by 2020.
If approved, Provenge would be the first "therapeutic" cancer vaccine. While conventional vaccines prevent disease, Provenge treats the condition.
"With the (application) submission complete, we have taken an important step towards reaching our goal of bringing a new therapy to men with advanced prostate cancer," Dendreon Chief Executive Mitchell Gold said in a statement.
Dendreon in September said it will be able to make enough Provenge to generate potential sales of $60 million to $125 million in the second half of next year.
The company said it will steadily ramp up production until full capacity is achieved by late 2011 at plants in New Jersey, Atlanta and Los Angeles, together able to support potential annual sales of $1.2 billion to $2.5 billion.
Prostate cancer is diagnosed in one of every six American men and is the second-leading cause of cancer death among men.
Dendreon shares [DNDN
Loading...
()
], which have soared 10-fold since March, were up 5 percent in morning trading on Nasdaq.
Print
Email
- A diet high in fat and sugar might actually be good for your portfolio.
- Warren Buffett and Bill Gates discuss the economy and other subjects with CNBC's Becky Quick.
- From the AIG&T to the Merrill Lychee, Jane Wells lists this year's fashionable holiday cocktails.
- One shopper explains why – aside from the prices – he gets up at 3am on the day after Thanksgiving to go shopping every year.
- Congressman Ron Paul explains to Squawk Box why he’s pushing legislation to audit the Federal Reserve.
- …you'll want to be prepared. Tips for getting the most out of the post-Thanksgiving shopping frenzy.
Data is a real-time snapshot *Data is delayed at least 15 minutes